EDUCATION 

Free for ICHS members (log in first for this option.)

Non-members: $25USD - includes a one year membership

Register

This webinar will be a case-based educational webinar that transitions naturally into discussion of
current evidence and future implementation of HPIs.

Join ICHS for an interactive, case-based webinar where real-world scenarios set the stage for a dynamic discussion on the latest evidence and the outlook of Helicase Primase Inhibitors (HPIs). This session will reflect the evolution of the field with the future introduction of HPIs, the available clinical evidence, and how these therapies may be integrated into
future practice.

Dr. Roy Chemaly will facilitate a moderated discussion with the presenters to provide attendees with both the scientific rationale and the clinical context for incorporating HPIs into future management strategies for Refractory HSV in immunocompromised patients.

During the webinar we will:

• Analyze compelling cases that mirror major challenges

• Explore current research shaping best practices

• Envision practical strategies for future implementation

Webinar Agenda includes:

• Case Presentation & Current Management – Dr. Joseph Sassine
• Helicase-Primase Inhibitor Overview & Phase 2 Data – Dr. Camille Kotton
• Phase 3 Clinical Evidence & Real-World Perspective - Dr. Zenia Papanicolaou
• Moderated Discussion & Audience Q&A – Dr. Roy Chemaly

Whether you are looking to sharpen your clinical reasoning or stay ahead of emerging trends, this session offers evidence driven insight and actionable takeaways.

Reserve your spot today and be part of the conversation shaping tomorrow’s HPI landscape.

Faculty Bios (alpha order):

Dr. Roy Chemaly

Dr. Camille Kotton

Dr. Genovefa (Zenia) Papanicolaou

Dr. Joseph Sassine